Roche Diagnostics Expands its Footprint into Kuwait

• In a move to expand its presence in the Middle East , Roche Diagnostics has now officially established its new legal entity in Kuwait supported by the Kuwait Direct Investment Promotion Authority (KDIPA), license to operate allows the biotechnology company to expand its local diagnostic operations and footprint

• New entity highlights Roche’s commitment to increase access to the latest diagnostic solutions & technologies for optimal patient care, at a time where having the right diagnostic tools is becoming more and more crucial

Kuwait City, Kuwait, 1st November 2020: Roche Diagnostics, a world leader in biotechnology, announced today the official establishment of its new legal entity in Kuwait; an important milestone that grants the company the opportunity to expand its local footprint, as part of its long-standing commitment to serving patients and communities across the country and the Middle East.

Supported by the Kuwait Direct Invest Promotion Authority (KDIPA), the company’s new license will allow for the expansion of local diagnostics operations and increased access for healthcare providers to the latest diagnostic tests; at a time where the demand for testing has increased, especially during COVID-19.

Moreover, this move further aligns with Roche’s commitment to serve the government and people of Kuwait by upscaling and expanding diagnostic testing and reinforcing the highest global standards and knowledge in the field where needed.

“We are very pleased to announce the official commencement of our legal presence in Kuwait today” said Dr. Vassilis Bakoyiannis, General Manager at Roche Diagnostics Kuwait. “We are also grateful for all the efforts deployed by the Kuwait Direct Investment Promotion Authority in enhancing Kuwait’s position as an innovation-based investment hub in the region, and value the country’s unwavering commitment towards further elevating the standards of healthcare,” he added.

The establishment of Roche’s new legal presence in Kuwait underscores the company’s dedication to supporting the Kuwaiti government in providing healthcare solutions relating to the prevention, diagnosis of various disease areas, including cardiovascular health, women’s health, infectious diseases, and others. Furthermore, Roche’s presence in Kuwait will expedite the company’s efforts in bringing the latest innovations and diagnostic technologies to support in upscaling patient care in the country’s healthcare institutions.

“By bringing in the latest diagnostic innovations to the country, we are able to better support healthcare professionals to make accurate and reliable clinical decisions. We are pleased to strengthen our presence in Kuwait and be closer to our patients and partners. Our mission remains to have our innovations accessible for every patient who needs them,” said Dr. Bakoyiannis.

RDME has taken the unprecedented step of being the first IVD Company to have a Management Centre and a logistics hub in the Middle East. RDME has extended its ownership of the entire supply chain, quality control and customer support all the way into the centre of the region. This base of operations reinforces the commitment to global Roche standards and is driven by a full team of vastly experienced specialists offering a complete portfolio of services. With this regional empowerment, RDME has moved its leadership and decision-making closer to its customers and distributors. These investments allow RDME to develop from being a supplier into becoming the preferred IVD partner for its customers.

RDME offers a complete portfolio of products and related services in 16 countries: UAE, Saudi Arabia, Iraq, Iran, Qatar, Kuwait, Bahrain, Oman, Yemen, Syria, Jordan, Palestine, Lebanon, Egypt, Libya and Maldives. This portfolio is supported locally by a vast network of trusted partners, agents and distributors.